Fluorocarbon Vector Antigen Constructs for Cellular Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunological strategies face challenges in developing vaccines and immunotherapeutics that effectively stimulate robust, durable cellular immunity, particularly for HIV, due to limitations in antigen delivery to immune responsive cells, safety concerns, scalability, and cost issues.
Innovation Solution
The use of a novel fluorocarbon vector, comprising perfluorocarbon or mixed fluorocarbon/hydrocarbon radicals, to enhance antigen delivery by forming covalent or non-covalent linkages with antigens, facilitating their uptake by antigen-presenting cells and optimizing immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antigen delivery methods are used, then the vaccine can be manufactured and administered, but the antigen delivery to immune responsive cells is insufficient, resulting in weak cellular immune responses
Solution Approach 1:
The patent introduces fluorocarbon vectors as intermediary carriers that bind to antigens and facilitate their delivery to antigen-presenting cells. The vector acts as a mediator between the antigen and the immune system, enhancing uptake through specialized cellular mechanisms that recognize fluorocarbon structures.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the antigen by conjugating it to fluorocarbon vectors, changing properties such as hydrophobicity, molecular weight, and cellular recognition characteristics. These parameter changes enable enhanced cellular uptake and improved immunogenicity.
2Productivity
If live attenuated vaccines or live vectors are used to deliver antigens, then cellular immune responses can be stimulated, but safety concerns arise
Solution Approach 1:
The patent employs synthetic fluorocarbon-vector-antigen conjugates as non-living, chemically defined delivery systems that are stable, scalable, and free from the safety concerns associated with live biological vectors. These synthetic constructs provide durable immunity without the risks of replication or mutation.
3Ease of manufacture
If peptide antigens are administered alone, then the formulation is simple, but the immunogenicity is insufficient to elicit robust cellular immunity
Solution Approach 1:
The patent creates composite structures by chemically conjugating fluorocarbon vectors to peptide antigens. This composite approach combines the simplicity of synthetic peptide production with the enhanced immunogenicity of fluorocarbon-based delivery systems, achieving both ease of manufacture and robust cellular immune responses.
Data Source
AI summary
The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.